All In Biotech

Drug Trial Radar · NCT05911763

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

Prospective, Observational , Multicenter Study of Effectiveness of Efanesoctocog Alfa on Long-term Joint Health in Patients With Hemophilia A

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 30, 2023

Primary completion

Jun 6, 2028

Study completion Sep 17, 2030

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating physician independently from the decision to include patients in the study. No study medication is provided. The data related to efanesoctocog alfa effectiveness, safety and usage will be collected prospectively during routine visits (expected annual/semi-annual visits) for up to 5 years following enrollment /treatment initiation.

Conditions

  • Hemophilia A

Interventions

  • Efanesoctocog Alfa BIVV001Drug

    Given per investigator's discretion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Annualized joint bleeding rate (AjBR) for treated bleedsTime frame: Up to 5 years
  2. Change from baseline in Annualized joint bleeding rate (AjBR) for all (treated and untreated) bleedsTime frame: Up to 5 years
  3. Number of Target joint development, resolution and/or recurrenceTime frame: Up to 5 years

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center- Site Number : 8400008

    Gilbert, Arizona

  • Loma Linda University- Site Number : 8400015

    Loma Linda, California

  • Orthopedic Institute for Children- Site Number : 8400004

    Los Angeles, California

  • The Center for Inherited Blood Disorders- Site Number : 8400001

    Orange, California

  • University of Colorado Hemophilia and Thrombosis Center- Site Number : 8400019

    Aurora, Colorado

  • William A. Shands Hospital at the University of Florida- Site Number : 8400032

    Gainesville, Florida

  • Johns Hopkins All Childrens Hospital - Outpatient Care Center - PIN- Site Number : 8400025

    St. Petersburg, Florida

  • Rush University Medical Center -1725 W Harrison St- Site Number : 8400014

    Chicago, Illinois

  • The Bleeding and Clotting Disorders Institute- Site Number : 8400005

    Peoria, Illinois

  • Indiana Hemophilia and Thrombosis Center- Site Number : 8400013

    Indianapolis, Indiana

  • University Of Iowa Hospitals And Clinics- Site Number : 8400026

    Iowa City, Iowa

  • ~Massachusetts General Hospital- Site Number : 8400017

    Boston, Massachusetts

  • Dana Farber and Boston Children's Hospital- Site Number : 8400031

    Boston, Massachusetts

  • University of Michigan Hospital - 1500 E Medical Center Dr- Site Number : 8400023

    Ann Arbor, Michigan

  • M Health Fairview- Masonic Cancer Clinic - Clinics- Site Number : 8400010

    Minneapolis, Minnesota

  • Mayo Clinic - PPDS- Site Number : 8400035

    Rochester, Minnesota

  • Mississippi Center For Advanced Medicine - 7731 Old Canton Rd- Site Number : 8400016

    Madison, Mississippi

  • University of Nebraska Medical Center - 985400 Nebraska Medical Center- Site Number : 8400009

    Omaha, Nebraska

  • Children's Specialty Center - Las Vegas- Site Number : 8400007

    Las Vegas, Nevada

  • Weill Cornell Medicine-New York Presbyterian Hospital- Site Number : 8400021

    New York, New York

  • Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400006

    Cincinnati, Ohio

  • Hemophilia Center of Western Pennsylvania- Site Number : 8400012

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center- Site Number : 8400003

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center-2001 Inwood Rd- Site Number : 8400020

    Dallas, Texas

  • University of Texas Southwestern Medical Center- Site Number : 8400011

    Dallas, Texas

  • Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400029

    Houston, Texas

  • Washington Institute for Coagulation- Site Number : 8400022

    Seattle, Washington

  • Blood Center of Wisconnsin- Site Number : 8400027

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.